Artesunate exerts protective effects against ulcerative colitis via suppressing Toll-like receptor 4 and its downstream nuclear factor-κB signaling pathways

被引:33
|
作者
Chen, Yu-Xuan [1 ]
Zhang, Xiao-Qi [1 ]
Yu, Cheng-Gong [1 ]
Huang, Shu-Ling [1 ]
Xie, Ying [1 ]
Dou, Xiao-Tan [1 ]
Liu, Wen-Jia [1 ]
Zou, Xiao-Ping [1 ]
机构
[1] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Gastroenterol, 321 Zhongshan Rd, Nanjing 210000, Jiangsu, Peoples R China
关键词
ulcerative colitis; artesunate; Toll-like receptor 4; nuclear factor-kappa B; anti-inflammatory; ARTEMISININ DERIVATIVES; APOPTOSIS; EXPRESSION; DISEASE; ACTIVATION; GROWTH;
D O I
10.3892/mmr.2019.10345
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Artesunate (ART) is a semi-synthetic derivative of artemisinin used in the treatment of patients with malaria, which has also been reported to have immunoregulatory, anticancer and anti-inflammatory properties. The aim of the present study was to investigate the possible beneficial effects of ART on ulcerative colitis (UC) rats and to detect the possible mechanisms underlying these effects. A UC rat model was established using dextran sulfate sodium (DSS). Rats were randomly divided into the following groups: Normal control, UC model group, UC rats treated with a low, medium or high dose of ART (10, 30 and 50 mg/kg/day, respectively), and the positive control group (50 mg/kg/day 5-aminosalicylic acid). The damage status of colonic mucosal epithelial tissue was investigated by hematoxylin and eosin staining, and then the weight, colon length and disease activity index (DAI) were measured. Western blotting and reverse transcription-quantitative polymerase chain reaction analysis were used to detect the levels of cytokines associated with UC and proteins associated with Toll-like receptor 4 (TLR4)-nuclear factor (NF)-kappa B pathway. ELISA was also performed to measure the levels of inflammatory cytokines. In addition, the viability and infiltration of RAW264.7 cells were examined using Cell Counting Kit-8 and Transwell assays. The results demonstrated that treatment with ART significantly alleviated the UC symptoms induced by DSS in the rat model, lowered the DAI, ameliorated pathological changes, attenuated colon shortening, inhibited the levels of pro-inflammatory mediators and myeloperoxidase activity, and increased hemoglobin expression. Additionally, inflammatory and apoptotic markers were found to be significantly downregulated following treatment with ART in UC rats and RAW264.7 cells. To the best of our knowledge, the present study is the first to demonstrate that ART exerts anti-inflammatory effects via regulating the TLR4-NF-kappa B signaling pathway in UC.
引用
收藏
页码:1321 / 1332
页数:12
相关论文
共 50 条
  • [21] Effects of Toll-Like Receptor 4 Inhibition on Transforming Growth Factor-β2 Signaling in the Human Trabecular Meshwork
    Sharma, Tasneem P.
    Curry, Stacy
    McDowell, Colleen M.
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 36 (03) : 170 - 178
  • [22] Protective Effect of Taraxasterol Against Myocardial Damage Caused by Sepsis Through Inhibition of Toll-Like Receptor 4/Nuclear Factor-Kappa B Signaling Pathway
    Wang, Shuquan
    Tang, Xuhui
    CURRENT TOPICS IN NUTRACEUTICAL RESEARCH, 2021, 19 (03) : 339 - 344
  • [23] Protective Effect of Ethanol Extract of Cuscuta chinensis on Lipopolysaccharide-induced Acute Kidney Injury via Suppressing the Toll-like Receptors 4-nuclear factor-κB Pathway
    Song, Wu
    Tao, Yuan
    Yang, Xiaofeng
    Bai, Xin-Yu
    Jiang, Shuang
    PHARMACOGNOSY MAGAZINE, 2018, 14 (56) : 383 - 389
  • [24] Targeting nuclear factor-κB suppresses the negative effect of Toll-like receptor 4 signaling on antimetastasis therapy based on targeting αvβ3
    Zhu, Jian-Hua
    Yuan, Ye
    Li, Dong
    Liao, Sheng-Jun
    Zhou, Yuan-Hong
    Wang, Qi
    Shu, Yu
    Yan, Bin
    Wei, Jing-Jing
    Sun, Rui
    Zhang, Gui-Mei
    Feng, Zuo-Hua
    CANCER SCIENCE, 2012, 103 (07): : 1319 - 1326
  • [25] Expression of genes encoding antimicrobial proteins and members of the toll-like receptor/nuclear factor-κB pathways in engineered human skin
    McFarland, Kevin L.
    Klingenberg, Jennifer M.
    Boyce, Steven T.
    Supp, Dorothy M.
    WOUND REPAIR AND REGENERATION, 2008, 16 (04) : 534 - 541
  • [26] Toll-like receptor 4 promotes proliferation and apoptosis resistance in human papillomavirus-related cervical cancer cells through the Toll-like receptor 4/nuclear factor-κB pathway
    Jiang, Ninghong
    Xie, Feng
    Guo, Qisang
    Li, Ming-Qing
    Xiao, Jingjing
    Sui, Long
    TUMOR BIOLOGY, 2017, 39 (06)
  • [27] Dihydromyricetin protects against lipopolysaccharide-induced cardiomyocyte injury through the toll-like receptor-4/nuclear factor-κB pathway
    Zhou, Meng-Qiao
    Shao, Ling
    Wu, Jing
    Peng, Na
    Jin, Lu-Ping
    Wei, Guo-Zhen
    Cheng, Wei
    Deng, Chang-Jin
    MOLECULAR MEDICINE REPORTS, 2017, 16 (06) : 8983 - 8988
  • [28] Sulfate glycosaminoglycan from swim bladder exerts immunomodulatory potential on macrophages via toll-like receptor 4 mediated NF-κB signaling pathways
    Yang, Kun
    Jia, Xuejing
    Chen, Jing
    Wang, Zhuo
    Song, Bingbing
    Li, Rui
    Cheong, Kit-Leong
    Zhong, Saiyi
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 271
  • [29] Toll-like receptor expression in human keratinocytes:: Nuclear factor κB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent
    Mempel, M
    Voelcker, V
    Köllisch, G
    Plank, C
    Rad, R
    Gerhard, M
    Schnopp, C
    Fraunberger, P
    Walli, AK
    Ring, J
    Abeck, D
    Ollert, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 121 (06) : 1389 - 1396
  • [30] Neuroprotective Effect of Paeonol Mediates Anti-Inflammation via Suppressing Toll-Like Receptor 2 and Toll-Like Receptor 4 Signaling Pathways in Cerebral Ischemia-Reperfusion Injured Rats
    Liao, Wen-Yen
    Tsai, Tung-Hu
    Ho, Tin-Yun
    Lin, Yi-Wen
    Cheng, Chin-Yi
    Hsieh, Ching-Liang
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016, 2016